Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density in this randomized controlled trial publication.

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis.

In this 24-month study, the researchers report changes in bone turnover and bone mass after 12 months of daily injections of human parathyroid hormone 1-34 [hPTH(1-34)] and 12 months off treatment in postmenopausal women (mean age, 63 years) with osteoporosis treated with glucocorticoid and hormone replacement therapy.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.

Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy X-ray absorptiometry (DXA); and biochemical markers of bone turnover.

How the Study Was Run

The design is described as randomized.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis.

The subject headings attached to it are Absorptiometry, Photon, Bone Density, Calcium, Osteoporosis, Parathyroid Hormone, Peptide Fragments and Prednisone.

The authors tagged it with the keywords Non-programmatic.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in people with osteoporosis and bone density.

The publication is from 2000 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.